Content deleted Content added
Added doi-access. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. |
Citation bot (talk | contribs) Altered doi-broken-date. | Use this bot. Report bugs. | #UCB_CommandLine |
||
Line 49:
* monitoring and strengthening laboratory protocols around the world<ref name="10.1126/science.abm7796">{{cite journal | vauthors = Van Kerkhove MD, Ryan MJ, Ghebreyesus TA | title = Preparing for "Disease X" | language = EN | journal = Science | volume = 374 | issue = 6566 | pages = 377 | date = October 2021 | pmid = 34643114 | doi = 10.1126/science.abm7796 | s2cid = 238746506 | bibcode = 2021Sci...374..377V }}</ref>
** Work on coronaviruses at the Wuhan Institute of Virology was carried out at [[biosafety level]] 2 with level 4 being the most secure.<ref>{{cite news |title=Inside the risky bat-virus engineering that links America to Wuhan |url=https://www.technologyreview.com/2021/06/29/1027290/gain-of-function-risky-bat-virus-engineering-links-america-to-wuhan/ |access-date=21 February 2022 |work=MIT Technology Review |language=en|quote=Two years later, Daszak and Shi published a paper reporting how the Chinese lab had engineered different versions of WIV1 and tested their infectiousness in human cells. The paper announced that the WIV had developed its own reverse-genetics system, following the Americans' lead. It also included a troubling detail: the work, which was funded in part by the NIH grant, had been done in a BSL-2 lab."}}</ref> Level 3 containment is now recommended for SARS-CoV-2.<ref name="KauferTheisLau2020">{{cite journal | vauthors = Kaufer AM, Theis T, Lau KA, Gray JL, Rawlinson WD | title = Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent | journal = Pathology | volume = 52 | issue = 7 | pages = 790–795 | date = December 2020 | pmid = 33070960 | pmc = 7524674 | doi = 10.1016/j.pathol.2020.09.006 }}</ref> As of 2020, the [[CDC]] and other health agencies recommended handling non-SARS non-MERS human coronaviruses and SARS-related coronaviruses from wild animals at Biosafety Level 2 ''in vitro'' and Level 3 ''in vivo''.<ref name="BMBL_Sixth_2020">{{cite book | author = U.S. Centers for Disease Control and Prevention |title=Biosafety in Microbiological and Biomedical Laboratories |date=June 2020 |publisher=United States Department of Health and Human Services |edition=Sixth |pages=452 |url=https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2020-P.pdf}}</ref><ref name="HermanVerlindenBreyer2004">{{cite journal | vauthors = Herman P, Verlinden Y, Breyer D, Van Cleemput E, Brochier B, Sneyers M, Snacken R, Hermans P, Kerkhofs P, Liesnard C, Rombaut B | display-authors = 6 | title = Biosafety Risk Assessment of the Severe Acute Respiratory Syndrome (SARS) Coronavirus and Containment Measures for the Diagnostic and Research Laboratories | journal = Applied Biosafety | date = September 2004 | volume = 9 | issue = 3 | pages = 128–142 | issn = 1535-6760 | eissn = 2470-1246 | doi = 10.1177/153567600400900303 | pmid = | s2cid = 74181037 | url = }}</ref><ref name="PHAC_Corona_2022">{{cite web | author = Public Health Agency of Canada |title=Biosafety advisory: SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) |url=https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-directives-advisories-notifications/sars-cov-2.html |website=www.canada.ca |access-date=3 February 2023 |date=2 November 2021}}</ref>
** According to a study of Indian BSL-2 and BSL-3 facilities, "there are no national guidelines or reference standards available in India on certification and validation of biosafety laboratories"<ref>{{cite journal | vauthors = Mourya DT, Yadav PD, Khare A, Khan AH | title = Certification & validation of biosafety level-2 & biosafety level-3 laboratories in Indian settings & common issues | journal = The Indian Journal of Medical Research | volume = 146 | issue = 4 | pages = 459–467 | date = October 2017 | pmid = 29434059 | pmc = 5819027 |doi = 10.4103/ijmr.IJMR_974_16 |doi-broken-date =
** In a 2018 study it was suggested that there is a need "to update international laboratory biosafety guidance" "to globalize biosafety"<ref>{{cite journal | vauthors = Kojima K, Booth CM, Summermatter K, Bennett A, Heisz M, Blacksell SD, McKinney M | title = Risk-based reboot for global lab biosafety | language = EN | journal = Science | volume = 360 | issue = 6386 | pages = 260–262 | date = April 2018 | pmid = 29674576 | doi = 10.1126/science.aar2231 | s2cid = 5046071 | bibcode = 2018Sci...360..260K | url = https://ora.ox.ac.uk/objects/uuid:48494af3-3b4d-4434-8709-5f1e9a36d112 }}</ref>
** In the wake of the COVID-19 pandemic there was a "global surge in labs that handle dangerous pathogens" and as of 2022 some researchers "are concerned about [these]".<ref>{{cite journal | vauthors = Mallapaty S | title = COVID prompts global surge in labs that handle dangerous pathogens | journal = Nature | volume = 610 | issue = 7932 | pages = 428–429 | date = October 2022 | pmid = 36220900 | doi = 10.1038/d41586-022-03181-x | bibcode = 2022Natur.610..428M | doi-access = free }}</ref>
| |||